A phase III, randomized, open-label, multicenter clinical trial (ALCANZA, NCT01578499) was designed to evaluate single-agent brentuximab vedotin versus a control arm of the investigator’s choice of standard therapies, methotrexate or bexarotene, in patients with CD30-expressing primary cutaneous ALCL or MF [47]. The gene discussed is TNFRSF8; the disease is mycosis fungoides.